Welcome to our dedicated page for Omada Health SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
FETTER TREVOR reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Trevor Fetter reported an equity compensation grant and an internal ownership transfer. He received 888 restricted stock units (RSUs) of Common Stock under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees, with each RSU representing one share to be settled under program terms.
Following this grant, Fetter directly holds 24,421 shares of Common Stock. Separately, 111,200 shares were transferred from a limited liability company to a family trust for which he serves as trustee and beneficiary, resulting in indirect ownership of those shares.
Omada Health, Inc. director Julie D. Klapstein reported receiving an equity grant of 649 shares of Common Stock in the form of restricted stock units. These RSUs were awarded at no cash cost per share under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees.
After this grant, Klapstein directly holds a total of 21,965 shares of Common Stock. The RSUs each represent the right to receive one share of Common Stock, with settlement occurring on a date selected by the director under the program or as otherwise provided by the plan. This is a routine, compensation-related acquisition rather than an open-market purchase.
HILLEMAN JERYL L reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Jeryl L. Hilleman received an equity award rather than making a market purchase. She was granted 1,299 restricted stock units under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees. Each RSU represents one share of common stock, to be settled on a future date as provided by the program. Following this grant, she holds 26,519 shares of Omada Health common stock directly.
ROOT JONATHAN D reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Jonathan D. Root received a grant of 820 restricted stock units as part of the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees. Each unit represents one share of common stock, granted at no cash cost. Following this award, Root holds 191,877 shares of common stock directly, including the RSUs, with settlement to occur on a date selected under the program or as otherwise provided by that program.
Omada Health, Inc.’s Chief Executive Officer Sean P. Duffy reported an exercise-and-sell transaction in company stock. He exercised stock options for 12,942 shares at $8.28 per share and 12,944 shares at $5.82 per share, then sold 12,942 shares at a weighted average price of $22.6731 and 12,944 shares at $22.6968 in open-market trades. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026. Following these transactions, he directly holds 411,861 shares of common stock and continues to hold stock options covering 116,077 and 155,427 shares at the respective exercise prices. In addition, 851,659 shares are held indirectly through family trusts for his family members, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Omada Health, Inc. Chief Accounting Officer Craig Gracey reported a small, pre-planned exercise-and-sell sequence in common stock. She exercised stock options to acquire 1,042 shares at $6.57 per share and sold 1,042 shares in open-market trades at $22.00 and $23.00 per share. After these transactions, she directly holds 15,441 common shares, so the sales represent roughly a mid–single-digit percentage of her holdings. The filing notes the trades were made under a Rule 10b5-1 trading plan adopted on March 13, 2026.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported a small, routine insider transaction involving company common stock. On June 30, 2026, he exercised stock options to acquire 300 shares at $8.28 per share and sold 300 shares in an open-market transaction at $22.00 per share. After these transactions, he directly held 115,409 shares of Omada Health common stock. A footnote states the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2026, indicating the timing was planned in advance rather than a discretionary market-timing decision.
OMDA (Morgan Stanley Smith Barney LLC account) submits a Notice of Proposed Sale under Rule 144 for 25,886 shares of Common Stock to be sold on 07/01/2026 following the exercise of stock options with cash payment. The filing lists multiple 10b5-1 sales by Sean Duffy in June 2026, showing recent dispositions and gross proceeds.
The filing records individual 10b5-1 sales on 06/16/2026, 06/24/2026, 06/25/2026, and 06/26/2026 with share counts and aggregate sale amounts disclosed in each line.
OMDA reports a Form 144 notice showing an exercise and sale of 35,600 shares of Common Stock on 07/01/2026. The filing also lists multiple 10b5-1 sales by Steven Cook in June 2026 totaling tens of thousands of shares and several hundred thousand dollars in proceeds.
OMDA (Form 144) reports planned and recent Rule 144 sales of Common stock by a reporting holder. The filing lists a proposed sale of 637 shares tied to an exercise of stock options to occur on 07/01/2026 for cash. The filing also lists multiple 10b5-1 sales executed in June 2026, including 6,894 shares on 06/12/2026 for $120,123.06 and several smaller trades between 06/22/2026 and 06/30/2026.